THE FUTURE OF
BIO-TECHNOLOGY
Bio-Technology
At Numeral XII, biotechnology is at the heart of our mission to enhance human health and longevity. We invest in and support breakthrough innovations in stem cell therapy, genetic research, and regenerative medicine — helping to bring life-changing treatments to market.
Our BioTech portfolio blends scientific excellence with strategic support, enabling visionary companies to scale faster and impact lives globally. From cryopreservation to cellular rejuvenation, we’re building a future where advanced healthcare is accessible and transformative.
Together, we’re redefining what’s possible in human health.

The Future of Biotechnology Starts Here

Integrative & Regenerative Wellness
We combine cutting-edge regenerative therapies including stem cells, PRP, and BHRT with integrative medical care focused on nutrition, sleep, and lifestyle. Guided by precision diagnostics and CPET-driven insights, our personalized protocols deliver holistic, high-impact wellness.

Redefining Luxury Wellness
Celerevive blends advanced diagnostics, regenerative therapies, and personalised care in a luxurious setting to restore energy, vitality, and longevity. Our signature Immunometabolic Reboot Program targets the root causes of fatigue and ageing — guiding you on a transformative journey to renewed health.

Trusted Stem Cell Preservation
CryoSave South Africa has been a leader in cord blood stem cell preservation for over 20 years, serving more than 18,000 families. As a fully licensed and internationally accredited facility, we uphold the highest standards in the collection, processing, and long-term storage of life-saving stem cells.

Advancing the Frontiers of Biotech
By combining advanced stem cell preservation, regenerative medicine, and personalised wellness, we deliver a unified approach to long-term health and vitality. Backed by world-class science, precision diagnostics, and global standards, we’re shaping a new era of proactive, personalised care.
This is where biotech meets the future.